Tooraj Raoof, MD
Internal Medicine · Encino, CANPI 1467567131
Payments from drug & device makers
Across 741 payments — averaging $9250.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.1M
- Sanofi US Services Inc.$972K
- E.r. Squibb & Sons, L.L.C.$565K
- Taro Pharmaceuticals USA, Inc.$526K
- Janssen Research & Development, LLC$449K
- LEO Pharma AS$360K
- plus $903K from 23 others
Across 48 payments — averaging $3568.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arcutis Biotherapeutics, Inc.$137K
- Almirall LLC$20K
- Bausch Health US, LLC$4K
- Amryt Pharma Holdings Ltd$4K
- AbbVie$3K
- Eli Lilly$3K
What the payments were for
- Consulting fees$1,60033%
- Speaking & faculty fees$1,07922%
- Food & beverage$2,16445%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 370 | $3,079,767 |
| Sanofi US Services Inc. | 44 | $971,682 |
| E.r. Squibb & Sons, L.L.C. | 8 | $564,535 |
| Taro Pharmaceuticals USA, Inc. | 66 | $525,918 |
| Janssen Research & Development, LLC | 27 | $449,107 |
| LEO Pharma AS | 17 | $360,492 |
| Sun Pharmaceutical Industries Inc. | 96 | $355,181 |
| Sanofi Pasteur Inc. | 12 | $190,102 |
| Vanda Pharmaceuticals Inc. | 25 | $155,252 |
| VYNE Pharmaceuticals Inc. | 9 | $130,062 |
| Amgen | 9 | $20,508 |
| Incyte Corporation | 7 | $14,767 |
| Sanofi | 3 | $14,495 |
| Pfizer | 5 | $9,749 |
| Boehringer Ingelheim | 2 | $8,957 |
| Almirall LLC | 5 | $1,696 |
| Eli Lilly | 2 | $1,132 |
| Merz North America, Inc. | 19 | $813 |
| Angiodynamics, Inc. | 1 | $146 |
| Lilly USA, LLC | 1 | $125 |
| Arcutis Biotherapeutics, Inc. | 4 | $125 |
| Revance Therapeutics, Inc. | 2 | $50 |
| LEO Pharma Inc. | 1 | $33 |
| Lundbeck LLC | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Novartis | 1 | $30 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Acelrx Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Klisyri$1,600
- XEOMIN$362
- Auryon Laser System 100-120 Vac$146
- EBGLYSS$125
How this compares
$6,854,836 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 83 | $95,591 |
| MounjaroTirzepatide | 25 | $25,440 |
| OzempicSemaglutide | 20 | $23,350 |
| Diclofenac Sodium | 49 | $19,886 |
| EliquisApixaban | 13 | $8,515 |
| Ketoconazole | 382 | $8,223 |
| LivaloPitavastatin Calcium | 12 | $5,369 |
| DexilantDexlansoprazole | 11 | $3,269 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,154 |
| Dexlansoprazole DrDexlansoprazole | 12 | $2,037 |
| Tretinoin | 17 | $1,006 |
| Mometasone Furoate | 57 | $985 |
| Ciclopirox | 34 | $897 |
| Metronidazole | 19 | $789 |
| Atorvastatin Calcium | 102 | $665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Synthroid | $3,079,767 | $96,15195 claims |
| Lilly USA, LLCMounjaro | $125 | $25,44025 claims |
| PfizerEliquis | $9,749 | $8,51513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Encino
- Shahram JacobsEncino$4.7M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.